Benchmarking the Pharmaceutical Market by Drug Delivery to 2014

TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this report 3
PharmaVitae Explorer database 3
Chapter structure 4
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Drug delivery overview 6
Prescription pharmaceutical market by delivery mechanism, 2002–14 12
Chapter 3 Overview of drug delivery market 27
Key findings 27
Introduction to drug delivery 28
Chapter 4 Segmentation of the drug delivery market 34
Key findings 34
Segmentation of the drug delivery market 35
Segmentation by mode of delivery 37
Segmentation by technology type 45
Merging technology with commercial opportunity 48
Chapter 5 Sales analysis of the pharmaceutical market by drug delivery 50
Key findings 50
A delivery-focused sales analysis of the leading prescription pharmaceutical companies 51
Prescription pharmaceutical market by delivery mechanism 53
Drug delivery analysis of the leading pharmaceutical players by company 67
Drug delivery analysis of the leading pharmaceutical players by company 74
Chapter 6 Appendix 80
References 80
Abbreviations 80
Exchange rates 81
About Datamonitor 82
Datamonitor consulting 82
Disclaimer 84

TABLE OF TABLES
Table 1: Classification system employed to dissect the delivery technology space 35
Table 2: The principal modes of delivery in the pharmaceutical industry 37
Table 3: List of companies covered by PharmaVitae 51
Table 4: Exchange rates, 2009 81


TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: Drug delivery systems can improve the therapeutic and commercial performance of a pharmaceutical product 6
Figure 3: A selection of pharmaceutical players operating within the drug delivery space 8
Figure 4: Segmentation of the drug delivery space by technology type 9
Figure 5: Drug delivery system by mode of administration 10
Figure 6: Technology count vs global pharma market share by delivery mechanism 11
Figure 7: Prescription pharmaceutical market by delivery mechanism, sales ($m), 2002–14 12
Figure 8: Compound annual growth rates by delivery mechanism (%), 2008–14 13
Figure 9: Absolute sales growth by delivery mechanism between 2008 and 2014 ($m) 14
Figure 10: Therapy area forecasts segmented by delivery mechanism 15
Figure 11: Product lifecycle stage forecasts segmented by delivery mechanism 16
Figure 12: Technology type forecasts segmented by delivery mechanism 17
Figure 13: Top 20 companies ranked by 2008 oral sales 18
Figure 14: Top 20 companies ranked by 2008 injectable sales 19
Figure 15: Top 20 oral products ranked by 2014 sales 20
Figure 16: Top 20 injectable products ranked by 2014 sales 21
Figure 17: Drug delivery systems can improve the therapeutic and commercial performance of a pharmaceutical 29
Figure 18: Johnson & Johnson Risperdal franchise sales ($m), 2002–08 31
Figure 19: A selection of pharmaceutical players operating within the drug delivery space 36
Figure 20: Segmentation of drug delivery space by modality and technology 38
Figure 21: Segmentation of the drug delivery space by technology type 45
Figure 22: Drug delivery system by mode of administration 47
Figure 23: Technology count vs global pharma market share by delivery mechanism 48
Figure 24: Global pharmaceutical market by delivery mechanism 49
Figure 25: Prescription pharmaceutical market by delivery mechanism, sales ($m), 2002–14 53
Figure 26: Compound annual growth rates by delivery mechanism, 2008–14 54
Figure 27: Absolute sales growth by delivery mechanism between 2008 and 2014 ($m) 55
Figure 28: Long-term sales analysis across the delivery space 56
Figure 29: Therapy area forecasts segmented by delivery mechanism 57
Figure 30: Territory-specific forecasts segmented by delivery mechanism 58
Figure 31: Product lifecycle stage forecasts segmented by delivery mechanism 59
Figure 32: Technology type forecasts segmented by delivery mechanism 60
Figure 33: Age of drug forecasts segmented by delivery mechanism 61
Figure 34: Prescription drug sales of Big Pharma peer set by delivery mechanism 62
Figure 35: Prescription drug sales of Biotech peer set by delivery mechanism 63
Figure 36: Prescription drug sales of Generics peer set by delivery mechanism 64
Figure 37: Prescription drug sales of Japan peer set by delivery mechanism 65
Figure 38: Prescription drug sales of Mid Pharma peer set by delivery mechanism 66
Figure 39: Top 20 companies ranked by 2008 oral sales 67
Figure 40: Top 20 companies ranked by 2014 oral sales 68
Figure 41: Oral sales dependency versus long-term growth of the top 20 oral drug companies 69
Figure 42: Top 20 companies ranked by 2008 injectable sales 70
Figure 43: Top 20 companies ranked by 2014 injectable sales 71
Figure 44: Injectable sales dependency versus long-term growth of the top 20 injectables drug companies 72
Figure 45: Injectable sales dependency versus long-term growth of the top 20 injectables drug companies, biologic focus 2014 (%) 73
Figure 46: Top 20 oral products ranked by 2008 sales 74
Figure 47: Top 20 oral products ranked by 2014 sales 75
Figure 48: Oral growth drivers/resistors, 2008–14 76
Figure 49: Top 20 injectable products ranked by 2008 sales 77
Figure 50: Top 20 injectable products ranked by 2014 sales 78
Figure 51: Injectable growth drivers/resistors, 2008–14 79